Skip to content
value.today
MacroGenics, Inc. logo

MacroGenics, Inc.

MGNX
$238 Mmarket cap on Oct 13, 2026-61.8% since Jan 2024
Compare
World rank
#15,646
Revenue
$150 M
For year ending December-2025
Net income
$-75 M
-49.9% margin
SEC filing
Employees
427
As on 2021
value.today research

MacroGenics, Inc. in brief

MacroGenics, Inc. is a listed company in the Biotechnology industry, based in Rockville, Maryland, USA. It was founded in 2000. Its market value was $238 M on 13 October 2026, which makes it the 15,646th largest listed company in the world and the 3,049th largest in the USA on this site. In the year to December 2025 it had sales of $150 M and a net loss of $75 M. It employs about 427 people and Eric Blasius Risser is its chief executive. Its largest product and service lines by sales in 2025 were Collaborative and other agreements (58%), Contract manufacturing (35%) and Royalty revenue (6%). Its shares trade under the symbol MGNX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About MacroGenics, Inc.

MacroGenics is a Clinical Stage Biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody based therapeutics for the treatment of cancer. The company annual revenue is 64 million USD and 307 employees as on 2019. The headquarters is in USA.

MacroGenics, Inc. timeline

4 events, 2000–2022
  1. 2000
  2. 🏁
    · approximate
    Founded
  3. 2003
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2013
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 11 October 2013; shares registered for exchange trading on 7 October 2013.
  7. 2022
  8. 💰
    Record revenue of $152 million
    FY2022, the highest of the 8 years on record.

Events of MacroGenics, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$342 M$685 M$1.0 B$1.4 B2020202120222023202420252026

World rank over time

▼ down 4,927 places since 2020
2020-01-01: #10806#10,80620202021-01-01: #6994#6,99420212022-01-07: #9924#9,92420222022-12-25: #14480#14,48020222023-07-30: #16044#16,04420232024-01-05: #11263#11,26320242026-03-08: #9495#9,49520262026-08-01: #14563#14,56320262026-10-13: #15733#15,7332026

Rank in USA: #2,448 (Jan 2020) · #1,975 (Jan 2021) · #2,633 (Jan 2022) · #2,966 (Dec 2022) · #3,263 (Jul 2023) · #2,368 (Jan 2024) · #1,832 (Mar 2026) · #2,942 (Aug 2026) · #3,035 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
1.6×
Price / book
4.3×
Free cash flow yield
-34.9%
Net margin (TTM)
-34.6%
Operating margin
-48.7%
Return on equity
-92.6%
Liabilities / assets
78.4%
Revenue growth
-0.3%
R&D / revenue
98.4%
Revenue per employee
$350 K
Profit per employee
$-175 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $60M, net income $-171M$60MFY18Fiscal year ending Dec 2019: revenue $64M, net income $-152M$64MFY19Fiscal year ending Dec 2020: revenue $105M, net income $-130M$105MFY20Fiscal year ending Dec 2021: revenue $77M, net income $-202M$77MFY21Fiscal year ending Dec 2022: revenue $152M, net income $-120M$152MFY22Fiscal year ending Dec 2023: revenue $59M, net income $-9M$59MFY23Fiscal year ending Dec 2024: revenue $150M, net income $-67M$150MFY24Fiscal year ending Dec 2025: revenue $150M, net income $-75M$150MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$150M-0.3%$-73M$-75M-49.9%
Dec 2024$150M+155.3%$-111M$-67M-44.7%
Dec 2023$59M-61.3%$-168M$-9M-15.4%
Dec 2022$152M+96.2%$-121M$-120M-78.8%
Dec 2021$77M-26.2%$-203M$-202M-261.0%
Dec 2020$105M+63.4%$-131M$-130M-123.7%
Dec 2019$64M+6.8%$-177M$-152M-236.5%
Dec 2018$60M—$-171M$-171M-285.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-81M$2M$-83M$-1.18—
Dec 2024$-68M$4M$-72M$-1.07—
Dec 2023$-78M$2M$-80M$-0.15—
Dec 2022$-87M$4M$-91M$-1.95—
Dec 2021$-144M$6M$-150M$-3.37—
Dec 2020$-112M$6M$-118M$-2.47—
Dec 2019$-134M$4M$-139M——
Dec 2018$-153M$25M$-178M——

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$149M
Net income, trailing 12 months
$-51M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $19M, net income $-15M$19MDec ’24Three months to Mar 2025: revenue $13M, net income $-41M$13MMar ’25Three months to Jun 2025: revenue $7M, net income $-36M$7MJun ’25Three months to Sep 2025: revenue $53M, net income $17M$53MSep ’25Three months to Dec 2025 (from the annual report): revenue $76M, net income $-14M$76MDec ’25Three months to Mar 2026: revenue $21M, net income $-37M$21MMar ’26Three months to Jun 2026: revenue $33M, net income $20M$33MJun ’26Three months to Sep 2026: revenue $19M, net income $-20M$19MSep ’26

Latest quarter to Sep 2026: revenue $19M (-64.8% on a year earlier), net income $-20M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of MacroGenics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$150 M
Operating income
$-73 M
Net income
$-75 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$257 M
Total liabilities
$201 M
Total equity
$56 M

As of December-2025

Top 100 institutional investors in MacroGenics, Inc.#

As of Sep 30, 2026
131 institutions held 49.0 M shares (about 76.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 46.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in MacroGenics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.6,149,936+1,470,707 (+31.43%)9.62%$24 MNov 13, 2026
2Armistice Capital, LLC6,000,000+993,248 (+19.84%)9.39%$23 MNov 16, 2026
3Vanguard Capital Management LLC2,679,146+23,136 (+0.87%)4.19%$10 MNov 13, 2026
4Acadian Asset Management LLC2,542,431-212 (-0.01%)3.98%$10 MNov 9, 2026
5Two Sigma Investments, LP2,381,144-84,555 (-3.43%)3.73%$9 MNov 16, 2026
6Renaissance Technologies LLC2,179,430-453,320 (-17.22%)3.41%$8 MNov 12, 2026
7Mackenzie Financial Corp2,013,592+370,966 (+22.58%)3.15%$8 MNov 2, 2026
8Vanguard Portfolio Management LLC1,993,180+172,949 (+9.50%)3.12%$8 MNov 13, 2026
9Ra Capital Management, L.P.1,864,1760 (0.00%)2.92%$7 MNov 16, 2026
10Geode Capital Management, LLC1,752,610+176,061 (+11.17%)2.74%$7 MNov 6, 2026
11Marshall Wace, LLP1,343,462-272,758 (-16.88%)2.10%$5 MNov 13, 2026
12Wasatch Advisors LP1,260,901-757,980 (-37.54%)1.97%$5 MOct 13, 2026
13ADAR1 Capital Management, LLC1,234,595+1,104,773 (+850.99%)1.93%$5 MNov 16, 2026
14Millennium Management LLC1,197,594-1,176,702 (-49.56%)1.87%$5 MNov 16, 2026
15State Street Corp1,167,355+303,692 (+35.16%)1.83%$5 MNov 12, 2026
16Connor, Clark & Lunn Investment Management Ltd.1,078,571+78,159 (+7.81%)1.69%$4 MNov 10, 2026
17D. E. Shaw & Co., Inc.992,081-70,910 (-6.67%)1.55%$4 MNov 16, 2026
18Affinity Asset Advisors, LLC953,979-262,627 (-21.59%)1.49%$4 MNov 13, 2026
19Bank Of America Corp /de/892,453-1,595,799 (-64.13%)1.40%$3 MNov 16, 2026
20Jacobs Levy Equity Management, Inc776,956-225,318 (-22.48%)1.22%$3 MNov 16, 2026
21Pinnacle Associates LTD647,713+393,412 (+154.70%)1.01%$3 MOct 20, 2026
22Citadel Advisors LLC585,493+405,660 (+225.58%)0.92%$2 MNov 16, 2026
23Northern Trust Corp523,519+7,390 (+1.43%)0.82%$2 MNov 16, 2026
24Goldman Sachs Group Inc472,936-85,065 (-15.24%)0.74%$2 MNov 16, 2026
25Vanguard Fiduciary Trust Co448,747+28,641 (+6.82%)0.70%$2 MNov 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in MacroGenics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Nomura Asset Management International Inc.420,0000 (0.00%)0.66%$2 MNov 16, 2026
27FMR LLC419,014+335,396 (+401.11%)0.66%$2 MNov 10, 2026
28Diadema Partners LP262,059-112,344 (-30.01%)0.41%$1 MNov 16, 2026
29Panagora Asset Management Inc250,1540 (0.00%)0.39%$1 MNov 12, 2026
30Man Group plc237,468+49,279 (+26.19%)0.37%$1 MNov 16, 2026
31Nuveen, LLC194,534+62,781 (+47.65%)0.30%$1 MNov 10, 2026
32Charles Schwab Investment Management Inc192,639+4 (0.00%)0.30%$1 MNov 16, 2026
33Strs Ohio178,400+35,900 (+25.19%)0.28%$1 MOct 30, 2026
34LPL Financial LLC167,763-2,500 (-1.47%)0.26%$1 MNov 6, 2026
35XTX Topco Ltd148,605+72,546 (+95.38%)0.23%$1 MNov 16, 2026
36Russell Investments Group, Ltd.144,296+81,983 (+131.57%)0.23%$1 MNov 6, 2026
37SEI Investments Co137,714-26,990 (-16.39%)0.22%$1 MNov 10, 2026
38Bank of New York Mellon Corp135,089-468 (-0.35%)0.21%$1 MNov 5, 2026
39Informed Momentum Co LLC124,033-47,672 (-27.76%)0.19%$0 MNov 16, 2026
40Morgan Stanley118,713+25,925 (+27.94%)0.19%$0 MNov 13, 2026
41Jump Financial, LLC109,800New0.17%$0 MNov 13, 2026
42Amundi103,359-77,886 (-42.97%)0.16%$0 MNov 6, 2026
43Point72 Asset Management, L.P.100,870New0.16%$0 MNov 16, 2026
44Tudor Investment Corp Et Al90,676+74,327 (+454.63%)0.14%$0 MNov 16, 2026
45Invesco Ltd.83,901-19,084 (-18.53%)0.13%$0 MNov 12, 2026
46Alps Advisors Inc83,789+19,281 (+29.89%)0.13%$0 MNov 3, 2026
47UBS Group AG82,209+40,374 (+96.51%)0.13%$0 MNov 10, 2026
48Susquehanna Portfolio Strategies, LLC82,121-14,565 (-15.06%)0.13%$0 MNov 16, 2026
49Caption Management, LLC77,715New0.12%$0 MNov 16, 2026
50Ikarian Capital, LLC74,8930 (0.00%)0.12%$0 MNov 16, 2026
51Bridgeway Capital Management, LLC72,276-1,224 (-1.67%)0.11%$0 MNov 16, 2026
52Empowered Funds, LLC72,276New0.11%$0 MNov 13, 2026
53Rhumbline Advisers71,501+3,581 (+5.27%)0.11%$0 MNov 10, 2026
54Vanguard Global Advisers, LLC68,506+45,686 (+200.20%)0.11%$0 MNov 13, 2026
55Persistent Asset Partners Ltd66,733-28,638 (-30.03%)0.10%$0 MNov 13, 2026
56Franklin Templeton Inc65,866-238 (-0.36%)0.10%$0 MNov 12, 2026
57Dimensional Fund Advisors LP62,356-316,979 (-83.56%)0.10%$0 MNov 4, 2026
58Barclays PLC61,312+11,482 (+23.04%)0.10%$0 MNov 6, 2026
59Squarepoint Ops LLC60,654-56,724 (-48.33%)0.09%$0 MNov 9, 2026
60Velan Capital Investment Management LP60,0000 (0.00%)0.09%$0 MNov 16, 2026
61Graham Capital Management, L.P.55,334+7,878 (+16.60%)0.09%$0 MNov 16, 2026
62AQR Capital Management LLC55,015New0.09%$0 MNov 16, 2026
63Deutsche Bank AG\54,600-7,731 (-12.40%)0.09%$0 MNov 6, 2026
64Price T Rowe Associates Inc /MD/51,5600 (0.00%)0.08%$0 MNov 16, 2026
65Los Angeles Capital Management LLC49,589New0.08%$0 MNov 12, 2026
66Employees Retirement System of Texas46,565New0.07%$0 MNov 10, 2026
67Quadrature Capital Ltd45,941New0.07%$0 MNov 13, 2026
68AlphaCore Capital LLC38,590+840 (+2.23%)0.06%$0 MNov 4, 2026
69Spark Investment Management LLC38,200+21,000 (+122.09%)0.06%$0 MNov 13, 2026
70DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main36,4670 (0.00%)0.06%$0 MNov 16, 2026
71Pathstone Holdings, LLC32,070New0.05%$0 MNov 13, 2026
72Susquehanna International Group, LLP32,065-21,554 (-40.20%)0.05%$0 MNov 16, 2026
73Jpmorgan Chase & Co31,395+5,024 (+19.05%)0.05%$0 MNov 12, 2026
74MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.30,341+1,541 (+5.35%)0.05%$0 MNov 16, 2026
75Corient Private Wealth LP30,0000 (0.00%)0.05%$0 MNov 16, 2026
76Achmea Investment Management B.V.29,700New0.05%$0 MOct 30, 2026
77MetLife Investment Management, LLC29,099-8,245 (-22.08%)0.05%$0 MNov 16, 2026
78Lantern Wealth Advisors, LLC26,700+4,000 (+17.62%)0.04%$0 MOct 22, 2026
79Cresset Asset Management, LLC25,827-1 (0.00%)0.04%$0 MNov 16, 2026
80XML Financial, LLC24,8360 (0.00%)0.04%$0 MOct 29, 2026
81Prelude Capital Management, LLC22,705-3,595 (-13.67%)0.04%$0 MNov 16, 2026
82EntryPoint Capital, LLC22,640New0.04%$0 MNov 13, 2026
83Wells Fargo & Company/mn20,693-38,993 (-65.33%)0.03%$0 MNov 16, 2026
84Aigen Investment Management, LP20,488New0.03%$0 MNov 16, 2026
85Susquehanna Fundamental Investments, LLC19,826-10,075 (-33.69%)0.03%$0 MNov 16, 2026
86WINTON GROUP Ltd19,100New0.03%$0 MNov 12, 2026
87Police & Firemen's Retirement System of New Jersey18,5250 (0.00%)0.03%$0 MNov 9, 2026
88Boothbay Fund Management, LLC18,3340 (0.00%)0.03%$0 MNov 16, 2026
89Stifel Financial Corp17,588+3,087 (+21.29%)0.03%$0 MNov 12, 2026
90Manufacturers Life Insurance Company, The17,324-357 (-2.02%)0.03%$0 MNov 13, 2026
91Jane Street Group, LLC17,234-66,628 (-79.45%)0.03%$0 MNov 12, 2026
92BNP Paribas Financial Markets16,285-8,032 (-33.03%)0.03%$0 MNov 12, 2026
93Alliancebernstein L.P.15,7800 (0.00%)0.02%$0 MNov 16, 2026
94Vanguard Personalized Indexing Management, LLC15,706+818 (+5.49%)0.02%$0 MNov 16, 2026
95Voya Investment Management LLC15,263+3,018 (+24.65%)0.02%$0 MNov 10, 2026
96Sanders Morris Harris LLC12,345New0.02%$0 MOct 14, 2026
97New York State Common Retirement Fund11,7000 (0.00%)0.02%$0 MNov 17, 2026
98Prudential Financial Inc10,075-17,700 (-63.73%)0.02%$0 MNov 16, 2026
99Scotia Capital Inc.10,000New0.02%$0 MNov 10, 2026
100Simplex Trading, LLC7,593-31,228 (-80.44%)0.01%$0 MNov 4, 2026

All 131 institutional investors, with who bought and sold →

Mutual funds holding MacroGenics, Inc.#

99 funds hold shares worth $53 M (about 18.7% of the company). Since their previous reports 72 added shares and 15 sold, buying $21 M net.
Mutual funds holding MacroGenics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.93 M$9 M3.0%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.56 M$7 M2.4%<0.01%newJun 30, 2026
🇺🇸 Wasatch Ultra Growth FundWasatch Advisors LP1.12 M$5 M1.7%1.1%−22%Jun 30, 2026
🇺🇸 Wasatch Micro Cap FundWasatch Advisors LP771,218$4 M1.2%0.53%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.649,399$3 M1.0%<0.01%−0.4%Jun 30, 2026
🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc.551,029$3 M0.86%0.08%+26%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC683,332$3 M1.1%<0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors513,042$2 M0.80%0.02%newJun 30, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.437,607$2 M0.68%0.12%no changeJun 30, 2026
🇺🇸 Nomura Healthcare FundDelaware Management Company420,000$2 M0.66%0.26%no changeJun 30, 2026
🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc.421,515$2 M0.66%<0.01%+137%Jul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC303,029$1 M0.47%<0.01%+62%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors211,153$1 M0.33%0.06%+43%Jun 30, 2026
🇺🇸 Fidelity SAI Small-Mid Cap Momentum Index FundFidelity Management & Research Company LLC177,801$1 M0.28%0.02%newJul 31, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.146,320$1 M0.23%<0.01%−5.6%May 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.152,584$1 M0.24%<0.01%newJul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC117,414$1 M0.18%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC111,316$0 M0.17%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC89,040$0 M0.14%<0.01%no changeMay 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC73,500$0 M0.12%0.23%no changeJun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC67,454$0 M0.11%<0.01%newJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC83,633$0 M0.13%<0.01%newJul 31, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC62,334$0 M0.10%0.04%+56%Jun 30, 2026
🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC75,416$0 M0.12%0.11%+118%Jul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors55,874$0 M0.09%<0.01%newJun 30, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP65,703$0 M0.10%<0.01%−56%Jul 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC51,056$0 M0.08%0.02%newJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust54,571$0 M0.09%<0.01%+115%May 31, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC48,120$0 M0.08%<0.01%newJun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation46,100$0 M0.07%<0.01%newJun 30, 2026
🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.51,578$0 M0.08%0.02%newJul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC42,073$0 M0.07%<0.01%+58%May 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC45,905$0 M0.07%0.02%newJul 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC43,475$0 M0.07%<0.01%−61%Jul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.32,408$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.32,184$0 M0.05%<0.01%−16%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.40,000$0 M0.06%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.31,781$0 M0.05%<0.01%−17%Jun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.29,153$0 M0.05%<0.01%+52%Jun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC30,003$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC29,881$0 M0.05%<0.01%newJul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.21,600$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC21,173$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors20,334$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Allspring Disciplined Small Cap FundAllspring Funds Management, LLC18,863$0 M0.03%0.05%newJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC17,851$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P.21,557$0 M0.03%0.02%newJul 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC20,852$0 M0.03%<0.01%+3.3%Jul 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC15,251$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC14,018$0 M0.02%0.03%+32%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC13,911$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS13,923$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC13,600$0 M0.02%<0.01%−2.2%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC13,411$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP15,624$0 M0.02%<0.01%+35%Jul 31, 2026
🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC12,187$0 M0.02%0.04%newJun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC11,251$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc.10,990$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.9,845$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.9,470$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC11,003$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC8,463$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC8,203$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC7,890$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC7,890$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC7,755$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC8,766$0 M0.01%<0.01%+0.2%Jul 31, 2026
🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds6,392$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC7,355$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC6,400$0 M0.01%<0.01%−87%May 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management5,700$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.7,071$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.5,496$0 M<0.01%<0.01%−18%Jun 30, 2026
🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.5,420$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC5,017$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS5,028$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC4,942$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC4,500$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC4,490$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS5,536$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC4,217$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC4,126$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC4,178$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP3,958$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 JNL/DFA U.S. Core Equity FundJackson National Asset Management, LLC3,147$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 LVIP Dimensional U.S. Core Equity 1 FundLincoln Financial Investments Corporation2,941$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC2,915$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation2,522$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC2,179$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,586$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC1,522$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP1,871$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 AZL DFA U.S. Core Equity FundAllianz Investment Management LLC1,449$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC1,433$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,282$0 M<0.01%<0.01%−16%Jun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC869$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP900$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC354$0 M<0.01%<0.01%+6.0%Jul 31, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC186$0 M<0.01%<0.01%newJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 99 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at MacroGenics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$129 K
1 sale, 1 insider
Net, 12 months
-$129 K
open market only
Insiders on file
30
since
$151 K-$2.1 M$0Dec 2023: bought $0 (0 trades), sold $190 K (1 trades)Dec 23Jan 2024: bought $0 (0 trades), sold $160 K (1 trades)Jan 24Feb 2024: bought $0 (0 trades), sold $1.8 M (5 trades)FebMar 2024: bought $0 (0 trades), sold $2.1 M (5 trades)MarApr 2024: bought $0 (0 trades), sold $799 K (5 trades)AprFeb 2025: bought $0 (0 trades), sold $1 K (1 trades)FebAug 2025: bought $151 K (2 trades), sold $0 (0 trades)AugAug 2026: bought $0 (0 trades), sold $129 K (1 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
MacroGenics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Ezio BonviniSr VP, Research & CSOOption exercise+8,000$2.600$21 K193,799Form 4
filed Jeffrey Stuart PetersSenior VP, GC, and SecretarySell10b5-1 plan-31,105$4.150$129 K0Form 4
filed Ezio BonviniSr VP, Research & CSOOption exercise+40,000$2.600$104 K185,799Form 4
filed William K. HeidenDirectorOption exercise+3,750——114,750Form 4
filed Edward HurwitzDirectorOption exercise+3,750——47,824Form 4
filed Margaret LiuDirectorOption exercise+3,750——14,750Form 4
filed Scott Thomas JacksonDirectorOption exercise+3,750——14,750Form 4
filed Meenu ChhabraDirectorOption exercise+3,750——14,750Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: MacroGenics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
4.9 M
7.8% of shares · 3.86 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-05-11 20:25 UTC, code T3, resumed 21:45 UTC

Fails to deliver

  • : 172 shares at $3.72
  • : 149 shares at $3.55
  • : 34 shares at $3.80
  • : 20,558 shares at $4.14
  • : 256 shares at $3.97

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

MacroGenics, Inc. scorecard#

Passes 6 of the 20 checks that could be worked out: strongest in profitability (2 of 5), weakest in growth (1 of 6). Fiscal year 2025; market cap of Oct 13, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median4.3×Price to book 4.3× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median1.6×Price to sales 1.6× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-34.9%Free cash flow is -34.9% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 6
    • ✗Revenue grew in the newest year-0.3%Revenue down 0.3% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-0.5%-0.5% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-0.5%-0.5% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-1.18 vs -1.07Diluted EPS -1.18 in fiscal 2025 against -1.07 the year before (report's currency).
    • ✓Net income higher than five years earlier-$75 M-$75 M in fiscal 2025 against -$130 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability2 of 5
    • ✗Profitable in the newest year-$75 MNet income -$75 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median-48.7%-48.7% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-86.9%-86.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-48.7%-48.7% in fiscal 2025 against -79.9% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities5.1×Current ratio 5.10 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-5.60Z-score -5.60 (distress zone) for fiscal 2025.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year0.8%Diluted shares up 0.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from MacroGenics, Inc.'s statements, beside the median of Biotechnology.

MacroGenics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-48.7%-60.5%
Net margin-49.9%-68.9%
Return on equity-86.9%-61.0%
Revenue growth, 3 years a year-0.5%12.9%
Revenue growth-0.3%15.8%
Free cash flow margin-55.5%-61.5%

3of 8on the Piotroski tests of financial strength

  • Revenue fell 0.3% against the year before.
  • Net loss of $75 million, the 13th loss-making year in a row.
  • Free cash flow was negative: -$83 million.

MacroGenics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

MacroGenics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue1501505915277105646015892
Cost of revenue00.80.63.42.700———
Research and development147177167207215193195191147122
General and administrative39715259634346413330
Total costs and expenses222261227273280236241231180152
Operating income−73−111−168−121−203−131−177−171−22−60
Interest expense and finance costs8.51.11.400—————
Other non-operating income (expense)6.19.49.71.70.71.325−0.22.51.5
Income before tax−75−66−9.1−120——————
Income tax−0.70.900000000
Net income attributable to shareholders−75−67−9.1−120−202−130−152−171−20−59
Earnings per share, basic-1.18-1.07-0.15-1.95-3.37-2.47——-0.54-1.69
Earnings per share, diluted-1.18-1.07-0.15-1.95-3.37-2.47——-0.54-1.69
Shares, weighted average (basic)63636261605248—3635
Shares, weighted average (diluted)63636261605248413635
Balance sheet
Cash and cash equivalents5718310110912318112622021284
Receivables0.4r4.3105610231330142.8
Inventory7.901.21.54.40————
Other current assets7.2r129.9102117————
Current assets220217251222280313240269322284
Property, plant and equipment2.1r182230384248575018
Right-of-use (leased) assets22r25242717r1920———
Total assets257262298280335379313332374311
Accounts payable3.3r5.06.44.9168.04.34.02.54.0
Current liabilities43565649755145605027
Lease liabilities (non-current)31r3330302125280——
Total liabilities201146146138968382897543
Retained earnings−1,244−1,170−1,103−1,094−974−772−642−490−312−293
Shareholders' equity56116153142240296231243299269
Total equity56116153142240296231243299—
Total liabilities and equity257262298280335379313332374311
Shares outstanding63636262615649423735
Cash-flow statement
Depreciation and amortization7.27.59.612111212r9.2r7.27.6
Share-based compensation14291820232120171512
Cash from operating activities−81−68−78−87−144−112−134−15314−44
Capital expenditure−1.9−3.7−1.8−3.6−6.2−5.9−4.3−25−29−11
Cash from investing activities−114149−8071−37−7.8−795778−70
Shares issued000.61.1118170119103340
Cash from financing activities701.01501.7123174120105351.9
Change in cash−12682−7.9−15−5855−948.4128−112
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What MacroGenics, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Collaborative and other agreements$87 M58%
  • Contract manufacturing$53 M35%
  • Royalty revenue$10 M6.5%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at MacroGenics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.1 M
Eric Blasius Risser
Other top executives, average
$1.2 M
the CEO earned 1.8× this
$100 invested is now
$7
MacroGenics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Eric Blasius Risser$2.1 M$1.5 M$1.2 M$7
2024Eric Blasius Risser$6.4 M$1.8 M$2.5 M$14
2023Eric Blasius Risser$3.7 M$6.5 M$1.7 M$42

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at MacroGenics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Acquisition or sale completed 1 · Directors and officers 7 · Material agreement 3 · Shareholder vote 2 · Results announced 9

MacroGenics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Acquisition or sale completed8-K
Shareholder vote8-K
Results announced8-K
Material agreement8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Material agreement8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of MacroGenics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2011$12 MNo. 1$10 to $50 million3equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at MacroGenics, Inc.#

1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $230 K a year.

Certified, FY2025
1
#1,910 among companies on value.today
Worker positions
1
Median wage offered
$230 K
a year, full-time
Applications filed
1
MacroGenics, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Senior Director, ToxicologyNatural Sciences Managers1$230 K

Where: Rockville, MD 1

MacroGenics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202511$230 K1
FY202344$117 K4
FY202211$69 K1
FY202122$112 K2
FY202033$99 K3

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as MacroGenics, Inc.

How MacroGenics, Inc. compares in Biotechnology

  • Market cap$238 M · higher than 47% of 726
  • Revenue$150 M · higher than 73% of 647
  • Net margin-34.6% · higher than 55% of 408
  • Revenue growth-0.3% · higher than 42% of 438
  • Price / sales1.6× · lower than 88% of 339
  • Price / book4.3× · lower than 36% of 534
  • FCF yield-34.9% · higher than 32% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
MacroGenics, Inc.🇺🇸$238 M—-34.6%-0.3%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 13, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at MacroGenics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show MacroGenics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about MacroGenics, Inc.? Suggest a correction